This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr Roger Whiting

Dr Roger Whiting

Name:

Dr Roger Whiting HonFBPhS

Organisation:

VM Pharma

Year elected:

2013

Affinity Group(s):

  • Drug Discovery, Development and Evaluation

Primary professional setting:

Industry

I have been a member of the BPS since 1976 and have spent my career in the Pharmaceutical industry, initially in the UK at Beecham Research Laboratories and Syntex Research Scotland. After transferring to Syntex in the USA I became Head of Basic Research, North America and in that capacity had overall responsibility for the research and early development of several compounds that subsequently achieved marketing approval including Cardene®, Toradol® and Aloxi®. As Head of the Neurobiology Business Unit of Roche Bioscience I oversaw two compounds progress into the Roche development pipeline. In 1999 I co-founded Roxro Pharma, which developed and obtained marketing approval for SPRIX® after which the company was acquired by DaiichI Sankyo. I was co-founder and CEO of Altos Therapeutics which developed ATC-1906M through Phase 1 clinical trials for the treatment of gastroparesis after which the company was acquired by Takeda. I’m a co-inventor on 25 patents, including Ranexa® which was approved for the treatment of angina. I currently serve on the Boards of VM Pharma, VM Oncology and VM Therapeutics and am Chairman of the SAB.